Mergers & AcquisitionsMedium•9 October 2026•
1 min read
Scancell Advances Nasdaq Listing via Neuphoria Therapeutics Merger
Key Facts
1Scancell Holdings is moving forward with its Nasdaq listing following an all-share merger with US-based Neuphoria Therapeutics.
2Shareholders are set to vote on the merger deal at a general meeting scheduled for October 20.
3The combined entity will trade under the ticker SCLT while retaining the Scancell name.
Scancell Holdings is moving forward with its Nasdaq listing following an all-share merger with US-based Neuphoria Therapeutics. Proactive Investors reported that shareholders are set to vote on the merger deal at a general meeting scheduled for October 20, with the combined entity expected to trade under the ticker SCLT while retaining the Scancell name.
The merger aims to facilitate a US listing for the cancer immunotherapy developer as it prepares for Phase III melanoma trials. Regarding related instruments, NEUP closed at $3.35 on October 8, 2026, while NDAQ closed at $92.37 on the same date.